Efficace F.,Italian Group for Adult Hematologic Diseases GIMEMA |
Baccarani M.,University of Bologna |
Rosti G.,University of Bologna |
Cottone F.,Italian Group for Adult Hematologic Diseases GIMEMA |
And 11 more authors.
British Journal of Cancer | Year: 2012
Background: Optimal adherence to imatinib therapy is of paramount importance to maximise treatment effectiveness in patients with chronic myeloid leukaemia (CML). The main objective of this study was to investigate patient-reported personal factors associated with adherence behaviour. Methods :Analysis was conducted on 413 CML patients receiving long-term therapy with imatinib. Adherence behaviour was measured with the Morisky Medication Adherence Scale and personal factors investigated included: quality of life, perceived social support, fatigue, symptom burden, psychological wellbeing and desire for additional information. Key socio-demographic and treatment-related factors were also taken into account. Univariate and multivariate logistic regression analyses were used to investigate factors associated with optimal adherence to therapy.Results:In all, 53% of patients reported an optimal adherence behaviour. The final multivariate model retained the following variables as independent predictors of optimal adherence to therapy: desire for more information (ref. no), odds ratio (OR)0.43 (95% confidence interval (CI), 0.29-0.66; P<0.001), social support (higher score representing greater support), OR1.29 (95% CI, 1.11-1.49; P<0.001) and concomitant drug burden (ref. no), OR1.82 (95% CI, 1.18-2.80; P0.006). Conclusion :This study suggests that a higher level of social support, satisfaction with information received and concomitant drug burden are the main factors associated with greater adherence to long-term imatinib therapy. © 2012 Cancer Research UK All rights reserved.